文献速递甲状腺疾病

基因组测序分类器管理细胞学不确定甲状腺结节的结局

Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本研究在3家学术中心纳入2017年7月至2021年6月间Bethesda III或IV类细胞学且接受手术或至少1年超声随访的成人患者,评估Afirma基因组测序分类器(GSC)的诊断性能。结果显示GSC在Bethesda III和IV结节中敏感性分别为95%和94%,特异性81%和82%,阳性预测值50%和65%,阴性预测值99%和98%,总体假阴性率2%。

要点

  • GSC对Bethesda III和IV结节阴性预测值分别为99%和98%,总体假阴性率2%。
  • 嗜酸细胞为主结节的GSC阴性预测值在Bethesda III为100%、IV为98%,但阳性预测值低(III为17%、IV为45%)。
  • GSC良性结节仅22%在随访中增大,可类似良性细胞学结节进行观察。

核心结论

  • GSC是管理细胞学不确定结节(包括较高风险的Bethesda IV类)的关键工具,GSC良性结节可类似良性细胞学结节进行观察。

研究设计与样本

  • 在3家主要学术中心纳入2017年7月至2021年6月间接受活检且细胞学为Bethesda III或IV类的成人患者,所有患者接受手术或至少1年超声监测随访,共834个不确定结节。

主要发现

  • 834个不确定结节的中位大小为2.1 cm,中位随访23个月。
  • GSC在Bethesda III结节中的敏感性、特异性、阳性预测值、阴性预测值分别为95%、81%、50%、99%。
  • GSC在Bethesda IV结节中的敏感性、特异性、阳性预测值、阴性预测值分别为94%、82%、65%、98%。
  • 总体假阴性率为2%;嗜酸细胞为主结节的GSC阴性预测值在Bethesda III为100%、Bethesda IV为98%,阳性预测值低(Bethesda III为17%、Bethesda IV为45%)。
  • 仅22%的GSC良性甲状腺结节在监测期间增大。

临床怎么用

  • 作者认为GSC是管理细胞学不确定患者(包括较高风险的Bethesda IV类)的关键工具,GSC良性甲状腺结节可类似良性细胞学结节进行观察。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Molecular testing can refine the risk of malignancy in thyroid nodules with indeterminate cytology to decrease unnecessary diagnostic surgery. OBJECTIVE: This study was performed to evaluate the outcomes of cytologically indeterminate thyroid nodules managed with Afirma genomic sequencing classifier (GSC) testing. METHODS: Adult patients who underwent a biopsy at 3 major academic centers between July 2017 and June 2021 with Bethesda III or IV cytology were included. All patients had surgery or minimum follow-up of 1 year ultrasound surveillance. The primary outcomes were the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of GSC in Bethesda III and IV nodules. RESULTS: The median nodule size of the 834 indeterminate nodules was 2.1 cm and the median follow-up was 23 months. GSC sensitivity, specificity, PPV, and NPV across all institutions were 95%, 81%, 50%, and 99% for Bethesda III nodules and 94%, 82%, 65%, and 98% for Bethesda IV nodules, respectively. The overall false-negative rate was 2%. The NPV of GSC in thyroid nodules with oncocytic predominance was 100% in Bethesda III nodules and 98% in Bethesda IV nodules. However, the PPV of oncocytic nodules was low (17% in Bethesda III nodules and 45% in Bethesda IV nodules). Only 22% of thyroid nodules with benign GSC results grew during surveillance. CONCLUSION: GSC is a key tool for managing patients with indeterminate cytology, including the higher-risk Bethesda IV category. GSC-benign thyroid nodules can be observed similarly to thyroid nodules with benign cytology.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Ahmadi S, Kotwal A, Bikas A, et al. Outcomes of Cytologically Indeterminate Thyroid Nodules Managed With Genomic Sequencing Classifier. J Clin Endocrinol Metab. 2024. PMID: 38415829. doi:10.1210/clinem/dgae112

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。